PT ENSEVAL PUTERA MEGATRADING TbkCOMPANY UPDATE

YTD 30 SEPTEMBER 2010 RESULTS

Table of Contents

• Enseval In BriefSection

I

• Business Overview Section

II

• Operational HighlightsSection

III

• Financial HighlightsSection

IV

I. Enseval In Brief

-

1,000

2,000

3,000

4,000

5,000

6,000

7,000

8,000

9,000

Net Sales

(100)

(50)

-

50

100

150

200

250

300

350

Laba (Rugi) Bersih

Sustainable Growth during last 15 years

1973:PT Ensevalestablished in Oct 1973

1973 1993

1993 :Trading & distribution activities transferred to subsidiary, Arya Gupta Cempaka, later known as PT EPM

1994

1994: The Company was listed on Indonesian Stock Exchange

2003

2003: Incorporation of Subsidiary PT Milenia Dharma Insani

2007

2007: Incorporation of Subsidiaries PT EnsevalMedika Prima & PT Global Chemindo Megatrading

2008

2008: Incorporation of Subsidiaries PT RenalmedTiara Utama

Milestones

• Largest Pharmaceutical distribution company in Indonesia with 42 full-service branches, 2 Regional Distribution Company and 23 branches under subsidiary & employs more than 5.000 employees

Market Leading Position in Indonesia

• Distributes more than 10 well known OTC products, nutrition products, infant milk, energy drinks and Ethical Products

Strong Product Portfolio & Diversification

• Public listed company with professional management that ensure fairness treatment to all Principals & all stakeholders

Good Corporate Governance

• Strong Net Sales growth with CAGR 12.6% from year 2005-2009 • Robust balance sheet figures

Strong Financial Track Record

• Committed for continuous improvement (ISO 9001:2008, GDP & OHSAS)

• Commitment to always increase market coverage and to invest and own directly all its assets, land, building, IT infrastructure, and transportation armada to serve better

Enseval’s Commitment Towards Improvement

Enseval In Brief

Shareholding Structure

PT Enseval PuteraMegatrading

Tbk

PT Tri Sapta Jaya

99.9%

PT MileniaDharma Insani

100.0%

PT EnsevalMedika Prima

100.0%

PT Global ChemindoMegatrading

100.0%

PT Renalmed Tiara Utama

97.5%

Kalbe 83.75%

Publik16.25%

II. Business Overview

Distribution & LogisticProduct Range : Ethical, OTC, Consumer Products, Medical Device &

Raw Material

Our service :

Warehousing

Inventory Management

Freight & Transportation

Sales & Support

Order-taking, Billing & Collection

Distribution & Logistic

Covers more than 150.000 outlets throughout Indonesia

Cover most pharmacies & hospital

Cover 80% of consumer & health market

24 hour order fulfillment & 4-5 hour order fulfillment for prescription

medicines

24 hour service for life saving drug

Offers value added services to customers

Medical DeviceProduct Range : Consumables, Instruments, Laboratories & Diagnostics, and

Products related to Laboratories Industry

The Company offers Marketing services for medical devices through its subsidiary, PT Enseval Medika Prima and Hemodialysis Treatment in collaboration with clinics and hospitals through PT Renalmed Tiara Utama.

The company has retained the trust & maintained good relationships with multi-national principals

Raw Material

Related to : Pharmaceutical Product, Food, Cosmetics & Veterinary

PT Global Chemindo Megatrading offers trading & marketing ofraw material and has extensive network and collaboration withMultinational Companies from different countries, such as : UnitedStates, Europe, China, Japan, Korea and other countries.

Healthcare Services Healthcare Services through Mitrasana Clinics ,with facilities such as:

Clinic, Pharmacy, Laboratory & Mini market, which now also offers Hemodialysis treatment.

Until 30 Sept 2010, The Company has 20 Clinics in Jakarta and its greater areas

Offered in 2 business models : direct investment & collaboration / joint operation models

III. Operational Highlights

Branches The largest pharmaceutical distribution network throughout theIndonesian Archipelago with 42 Branches (EPM), 2 Regional DistributionCenter, Located in Jakarta & Surabaya & 23 Branches under subsidiarycompany (TSJ)

Events Highlights in 2010

The Company awarded as ‘Pharmaceutical distribution Company that has the most outlet’ from Rekor Bisnis Indonesia in February

The Company conducted its AGMS on May 18, 2010

In June 2010, PT Perkebunan Nusantara VIII joined as new principal with its ready to drink tea product ‘ Walini Tea’

Operationals Highlights in 2010

Infrastructures & Branches Development in branches, such as : Aceh, PematangSiantar, Solo, Jember & Banjarmasin

The Company has completed audit for OHSAS (Occupational Health & Safety Certification for its Logistic Department

Some initiatives for service quality improvement: - Enseval Customer Care (ECC) Implementation - Subdistributor Appointment to expand distribution coverage throughout Indonesia- 24 hours Call Center Implementation, ‘After Sales Service’ & ‘Customer Service Online’ in PT Enseval Medika Prima, The Company’s Subsidiary

From IT point of view, The Company has completed Oracle ERP version upgrade & Oracle Demantra Implementation (Sales Forecasting System)

The Company Subsidiary, PT Enseval Medika Prima & PT Global Chemindo Megatradinghave been known in Medical Devices & raw material market in Indonesia & gained trust from Multinational Principals

The Company open 14 Mitrasana Clinics in Jakarta & its greater area in 2010, Until 30 Sept 2010, the Company has 20 Clinics

Corporate Social Responsibility‘Enseval Berbakti’ program :

Blood Donation, every 3 months in 42 branches

Plantation of more than 800 trees in the company’s 42 branches

Scholarship program for employees children

Human Resources Employs over 5,000 personnel with over 2,000 personnel are working in sales and

distribution

The Company continues to provide training for all employees to improved its human resources competencies

In year 2010, The Company continues to promote CONIM Program (ContinuosImprovement) to all staffs, both in Headquarters & in all Branches.

Principals Based on Categories

OTC Consumers Product Ethical

Major Principals

Principals Based on Categories

Medical Devices & Diagnostic Raw Material

Friesland Foods Domo

Major Principals

Infrastructures

More than 580 Transportation FleetMore than 120 Motorcycles

More than 61.000 Pallets Size

The Usage of Oracle System as IT Platform

IV. Financial Highlights

Financial Highlights

Net Sales Operating Income

Until YTD 30 Sept 2010, The Company recorded Net Sales of IDR 6.9 trillion, 12.1% growth YoY, with Operating Income amounting to IDR 206.5 billion

307

363

484

207

4.8%4.9%

5.7%

3.0%

0%

1%

2%

3%

4%

5%

6%

0

100

200

300

400

500

600

2007 2008 2009 YTD 09 2010

Laba Usaha Marjin Laba Usaha

6,4

7,4

8,6

6,9

15.4% 16.1%15.7%

12.1%

0%

2%

4%

6%

8%

10%

12%

14%

16%

18%

0

1

2

3

4

5

6

7

8

9

10

2007 2008 2009 YTD 09 2010

Penjualan Bersih (Miliar Rp) Pertumbuhan (%)

Financial Highlights

231

267

329

143

3.6%

3.6%3.9%

2.1%

0.0%

0.5%

1.0%

1.5%

2.0%

2.5%

3.0%

3.5%

4.0%

4.5%

0

50

100

150

200

250

300

350

2007 2008 2009 YTD 09 2010

Net Income (IDR Million) Net Profit Margin

Net Income

102

117

144

63

0

20

40

60

80

100

120

140

160

2007 2008 2009 YTD 09 2010

Net Income Per Share (IDR)

Net Income Per Share

Until YTD 30 Sept 2010, The Company Net Income reached IDR 143.1 million with Net Income Per Share of IDR 63

2,228

1,778

1,256

482 359

23

2,639

2,107

1,231

537

331

22

Consumer Products Ethical OTC Raw Material Medical Device Others

YTD 09 2009 YTD 09 2010

11.4%

5.2%

2.0%

18.5%

18.4%

7.8%

Net Sales By Division

Sales ContributionPada Periode 30 Sept 2010 ,Kalbe Group’s Net Sales Contributes 72% from total net sales , while the remaining 28% from 3rd party prinsipal .

72%

28%

72%

28%

Kalbe Grup

3rd Party

YTD 30 Sept 2010 YTD 30 Sept 2009

Sales Contribution

Consumer Products

38%

Ethical 31%

OTC 18%

Medical Device

8%

Raw Material 5%

Others0%

YTD 092010 233

315

502

673

FY 2006 FY 2007 FY 2008 FY 2009

310

414

581

714

FY 2006 FY 2007 FY 2008 FY 2009

4,979 5,639

6,310

7,163

FY 2006 FY 2007 FY 2008 FY 2009

CAGR 12,9%

Medical Device

Net Sales (in IDR Billion )

Raw Material

CAGR 42,3%

CAGR 32,1%

2,625

391

3,016 2,980

491

3,471

Current Assets Non Current Assets Total Assets

30 Sept 09 (IDR Billion) 30 Sept 10 (IDR Billion)

13.5%

25.8%

15.1%

Assets

1,482

45

1,527 1,701

86

1,787

Current Liablities Non Current Liabilities Total Liabilities

30 Sept 09 (IDR Billion) 30 Sept 10(IDR Billion)

Liabilities & Equity

1,489

1,684

Equity

30 Sept 09 (IDR Billion) 30 Sept 10 (IDR Billion)

17.0%

13.1%

91.0%

14.8%

Thank You For further information, please contact :

PT Enseval Putera Megatrading Tbk.

Enseval Building, Kawasan Industri Pulogadung

Jalan Pulolentut No.10

Jakarta 13920 – Indonesia

Phone : 62-21-46822422 Fax : 62-21-4609039

Website : www.enseval.com

Email : investor.relations@enseval.com

IMPORTANT NOTICE

This presentation has been prepared for informational purposes only by PT Enseval Putera

Megatrading Tbk. (“Enseval” or the “Company”).

The information contained in this Presentation does not purport to be all-inclusive or to

contain all of the information that may be material to an investor’s decision. It should be

noted that the information contained in this Presentation is subjected to further review, and

that such information may be updated and/or amended from time to time as

circumstances change or more information becomes available. Some of those revisions or

changes may be material.

Each recipient of this Presentation should therefore perform their own independent

analysis of the business, operations, financial condition, creditworthiness, status and

affairs of Enseval. Each recipient should also conduct their own enquiries into the

adequacy, accuracy, and completeness of any information relating to Enseval, as the

information and data contained in this Presentation are not substitutes for the recipient’s

independent evaluation and analysis.

This presentation is not an offering document and will be updated regularly as necessary.